“…Functionally, icv administration in adult Sprague-Dawley rats of the relaxin-3 agonist peptide, 'RXFP3-A2' , which is selective for RXFP3 over RXFP1 [40], reduced anxiety-like behaviour [33]. The precise brain sites influenced by RXFP3 to produce these behavioural changes in the anxiety tests studied are not known, but it might involve activation of RXFP3 strongly expressed within areas involved in aversion-motivated exploration such as the extended amygdala, the periaqueductal grey and hippocampus [29,[41][42][43].…”